| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 259.7 | 171.0 |
| Profit before tax | -12.8 | -47.2 |
| Net income | -12.9 | -47.2 |
| EPS (diluted, $ a share) | $-0.25 | $-0.94 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +51.9% |
|---|---|
| Operating margin | -4.3% |
10-Q filed with the SEC, NASDAQ: AXSM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Axsome Therapeutics, Inc.: key numbers
- Share price
- $135.95Close, Nov 17
- Market cap
- $7.15B
- Shares outstanding
- 52.6MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Axsome Therapeutics, Inc.
All →Axsome Therapeutics Financial Results
Axsome Therapeutics reported Q3 2026 financial results with total net product revenue of $259.7 million, a 52% year-over-year increase driven by strong sales of Auvelity and Sunosi. The company significantly narrowed its net loss to $12.9 million compared to $47.2 million in the prior year period, surpassing a $1 billion annual revenue run rate.
- Term
- Q3 2026
“Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate. We expect sustained momentum driven by strong underlying demand for Auvelity in major depressive disorder, and continued acceleration of new patient initiations in Alzheimer’s disease agitation.”
Herriot Tabuteau, MD, Chief Executive Officer of Axsome Therapeutics